A multicenter, randomized, active-controlled study to evaluate the safety and Tolerability of two blinded doses of Apelacimab (MAA868) compared with open-label Rivaroxaban in patients with Atrial Fibrillation.
Contact phone
517-364-5760
Contact email
[email protected]
Principal investigator
Dr. John Ip, MD
Trial Category
Heart & Vascular
Trial SubCategory
Atrial Fibrillation
Webform